Under one in 10 patients eligible to benefit from obesity jabs including Wegovy have access to them, caution the WHO as it releases its initial advice on the medications.
Considering over a billion individuals worldwide currently living with obesity, it is advocating for increased and just access to this class of drugs.
According to projections, over two billion will be obese by 2030 unless action is taken.
"Our latest guidelines recognises that obesity is a lifelong illness that can be managed with thorough and lifelong support," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are major hurdles to universal availability to the treatments that can help people shift substantial body mass, notes the body.
Weight-Loss Drug Supply Crisis
Even in the present most favorable outlook, the production of such drugs might only reach around 100 million people – fewer than 10% of the global need, as stated by the health organization.
The recommendation encourages countries and companies to expand access, through approaches such as licensing agreements.
The intellectual property rights on semaglutide – the primary ingredient of a leading brand – is set to lapse in a number of countries in 2026.
The Way Obesity Injections Operate
These medications imitate a body's own hormone to slow digestion, curb appetite and enhance satiety so people eat less.
Individuals commonly begin shedding pounds in the initial weeks of beginning the once-weekly jabs.
Research points to users may put most of the weight back on a year later of discontinuing the drug, because their typical appetite return.
To be overweight or obese increases your chance for experiencing diseases, like type 2 diabetes, heart disease, brain attack, and some malignancies.
Excess weight affects individuals in every country and was associated with 3.7 million deaths worldwide in 2024, per the health agency.
